Loading…
Loading…
How do you see this drug positioned relative to other newer eye drop therapies for the improvement of near vision
we saw a sequential improvement from 1Q's 56% to 2Q's 58%. Maybe if you could provide some more color on the key drivers of this improvement
if you can elaborate on the volume versus price drivers for key brands like Lipitor in developed markets in greater China
the guidance assumes a significant second half ramp in revenue, EBITDA, and earnings per share